Brian Piekos insider trades: KalVista Pharmaceuticals (KALV) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Brian reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | KALV | ↓ Sell | 1,489 | $26.78 | $40K | Direct | May 26, 2026 (4d) |
| Feb 23, 2026 | KALV | ↓ Sell | 1,767 | $15.57 | $28K | Direct | Feb 24, 2026 (1d) |
| Nov 24, 2025 | KALV | ↓ Sell | 4,471 | $13.45 | $60K | Direct | Nov 26, 2025 (2d) |
| May 14, 2021 | GMTX | ↑ Buy | 7,655 | $9.46 | $72K | Direct | May 18, 2021 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other KALV insiders
Open-market trades in the last 12 months
About Brian Piekos's insider trades
Brian Piekos is Chief Financial Officer at KalVista Pharmaceuticals (KALV). Since May 14, 2021, Brian has reported 1 open-market purchase worth $72K and 3 sales worth $128K on SEC Form 4. In the last 12 months: 3 sales ($128K).
Their filings also include grants and awards (9 filings), option exercises (3 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KALV insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.